Form 4: Hookipa Pharma Director Acquires Stock Options
SEC Filing
Director David Ross Kaufman acquired 49,000 stock options in Hookipa Pharma Inc. on June 17, 2024.
Summary
- David Ross Kaufman, a director of Hookipa Pharma Inc., filed a Form 4 to report changes in beneficial ownership.
- On June 17, 2024, Kaufman acquired 49,000 stock options with an exercise price of $0.71.
- These options vest on the earlier of June 17, 2025, or the date of the Issuer's next annual meeting of its stockholders.
- The options expire on June 17, 2034.
- Following the transaction, Kaufman directly owns 49,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/17/2024 | Date of transaction: Director acquired 49,000 stock options. |
| 06/17/2025 | Earliest vesting date for the stock options. |
| 06/17/2034 | Expiration date for the stock options. |
| 06/18/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.